Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 10/20 | 0.62 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3194063 | 1.00 | EPHX2 (0.62) | EPHX2EPHX1KMT2AMEN1LMNA | |
| SCHEMBL3183713 | 0.91 | EPHX2 (0.66) | EPHX2EPHX1KMT2AMEN1NPC1 | |
| SCHEMBL3183706 | 0.91 | EPHX2 (0.66) | EPHX2EPHX1KMT2AMEN1NPC1 | |
| SCHEMBL3181109 | 0.89 | EPHX2 (0.59) | EPHX2KMT2AMEN1SMN1; SMN2NPC1 | |
| SCHEMBL3181113 | 0.89 | EPHX2 (0.59) | EPHX2KMT2AMEN1SMN1; SMN2NPC1 | |
| SCHEMBL3178508 | 0.86 | EPHX2 (0.62) | EPHX2KMT2AMEN1ALDH1A1DRD2 | |
| SCHEMBL3178515 | 0.86 | EPHX2 (0.62) | EPHX2KMT2AMEN1ALDH1A1DRD2 | |
| SCHEMBL3182885 | 0.86 | EPHX2 (0.64) | EPHX2EPHX1KMT2AMEN1DRD2 | |
| SCHEMBL3182877 | 0.86 | EPHX2 (0.64) | EPHX2EPHX1KMT2AMEN1DRD2 | |
| SCHEMBL3183168 | 0.85 | EPHX2 (0.66) | EPHX2EPHX1KMT2AMEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7662910-B2 | Inhibitors for the soluble epoxide hydrolase | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-02-16 | — | — | US | claimed |
| US-10322118-B2 | Compounds and methods for inhibiting Cif virulence factor | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2019-06-18 | — | — | US | disclosed |
| US-20160206605-A1 | COMPOUNDS AND METHODS FOR INHIBITING CIF VIRULENCE FACTOR | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-07-21 | — | — | US | disclosed |
| US-20160206605-A1 | COMPOUNDS AND METHODS FOR INHIBITING CIF VIRULENCE FACTOR | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-07-21 | — | — | US | disclosed |
| US-20150045389-A1 | COMPOUNDS AND METHODS FOR INHIBITING CIF VIRULENCE FACTOR | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-12 | — | — | US | disclosed |
| US-20150045389-A1 | COMPOUNDS AND METHODS FOR INHIBITING CIF VIRULENCE FACTOR | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-12 | — | — | US | disclosed |
| US-8476043-B2 | Inhibitors for the soluble epoxide hydrolase | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476043-B2 | Inhibitors for the soluble epoxide hydrolase | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-07-02 | — | — | US | disclosed |
| US-20110021448-A1 | Inhibitors for the Soluble Epoxide Hydrolase | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110021448-A1 | Inhibitors for the Soluble Epoxide Hydrolase | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-01-27 | — | — | US | disclosed |
| US-7662910-B2 | Inhibitors for the soluble epoxide hydrolase | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160206605-A1 | COMPOUNDS AND METHODS FOR INHIBITING CIF VIRULENCE FACTOR | CFTR, NCF1, CFB | EPHX2 2083/4885EPHX1 1831/4885KMT2A 4511/4885 |
| US-20110021448-A1 | Inhibitors for the Soluble Epoxide Hydrolase | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885EPHX1 1/4885KMT2A 2899/4885 |
| US-10322118-B2 | Compounds and methods for inhibiting Cif virulence factor | CFTR, NCF1, CFB | EPHX2 2083/4885EPHX1 1831/4885KMT2A 4511/4885 |
| US-20150045389-A1 | COMPOUNDS AND METHODS FOR INHIBITING CIF VIRULENCE FACTOR | CFTR, NCF1, CFB | EPHX2 1975/4885EPHX1 1764/4885KMT2A 4436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.